Targeting the Oxysterol Receptor GPR183 to Mitigate Fibrogenesis in Idiopathic Pulmonary Fibrosis
Minh D. Ngo, Cheng X. Foo, Ziying Hong, Hoang P.L. Uong et autres
Abstract Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal lung disease with a median survival of 3-5 years after diagnosis. Current antifibrotic therapies slow disease progression, but do not halt or reverse fibrosis, underscoring the need for new therapies. We …
au, dk (code pays fourni par la source)
0 citations
bioRxiv (Cold Spring Harbor Laboratory)